US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pasithea Therapeutics Corp.

1.73

+0.01000.58%

Post-market: 1.750.0193+1.12%19:23 EDT

Volume:171.18K

Turnover:288.57K

Market Cap:4.68M

PE:-0.14

High:1.76

Open:1.76

Low:1.60

Close:1.72

Loading ...

Overview Company News Filings

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial

MT Newswires Live

BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer

Pasithea Therapeutics Corp - No Dose-Limiting Toxicities (Dlt's) or Rash Observed to Date

THOMSON REUTERS

Pasithea Therapeutics Corp - Src Recommended That Trial Escalate to Next Dose Level of 30Mg Capsule

THOMSON REUTERS

Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer

THOMSON REUTERS

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

Crude Oil Down 2%; ISM Services PMI Falls In January

US Stocks Mixed; Walt Disney Posts Upbeat Earnings

Pasithea Therapeutics Shares Rise After Positive Safety Review for Cancer Treatment

Top Premarket Gainers

MT Newswires Live

Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer

THOMSON REUTERS

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics opens three clinical trial sites in Eastern Europe

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

THOMSON REUTERS

Pasithea Therapeutics Corp - to Present Interim Safety and Pk Data in Q1 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KTTA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KTTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTA\",,,,,undefined,":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":1.73,"timestamp":1745611200000,"preClose":1.72,"halted":0,"volume":171179,"hourTrading":{"tag":"盘后","latestPrice":1.7493,"preClose":1.73,"latestTime":"19:23 EDT","volume":586,"amount":986.47,"timestamp":1745623422513},"delay":0,"floatShares":2592404,"shares":2705263,"eps":-12.685715,"marketStatus":"Market Closed","change":0.01,"latestTime":"04-25 16:00:00 EDT","open":1.76,"high":1.76,"low":1.6,"amount":288569.0219565,"amplitude":0.093023,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.685715,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":1.72,"preHourTrading":{"tag":"盘前","latestPrice":1.74,"preClose":1.72,"latestTime":"09:19 EDT","volume":2167,"amount":3770.3591827,"timestamp":1745587185122},"postHourTrading":{"tag":"盘后","latestPrice":1.7493,"preClose":1.73,"latestTime":"19:23 EDT","volume":586,"amount":986.47,"timestamp":1745623422513},"volumeRatio":0.8312488900756949},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTA\",,,,,undefined,":{"symbol":"KTTA","floatShares":2592404,"roa":"-42.23%","roe":"-72.83%","lyrEps":-12.685715,"volumeRatio":0.8312488900756949,"shares":2705263,"dividePrice":0,"high":1.76,"amplitude":0.093023,"preClose":1.72,"low":1.6,"week52Low":0.9226,"pbRate":"0.32","psRate":"9.62","week52High":7.69,"institutionHeld":0,"latestPrice":1.73,"eps":-12.685715,"divideRate":0,"volume":171179,"delay":0,"ttmEps":-12.685715,"open":1.76,"prevYearClose":3.15,"prevWeekClose":1.38,"prevMonthClose":1.3,"prevQuarterClose":1.3,"fiveDayClose":1.38,"twentyDayClose":1.32,"sixtyDayClose":2.48},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KTTA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DRUG","OPTHF","RLMD","ENVB","IXHL","QNTM","SEEL","ENTBF","ATAI","MNMD","SPRC","MYCOF","KTTA","NRXP","PBM","BK4007","ALID","BK4539","CMPS","BK4202","CMND","PHRRF","NUMIF","FLHLF","MIRA","GHRS","BETRF","CYBN","PSYGF","RVVTF","BK4139","BK4547","SILO","BK4168","AGNPF","MDXXF","SNPX"],"gpt_icon":0},{"id":"2529607368","title":"Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529607368","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529607368?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:02","pubTimestamp":1745492520,"startTime":"0","endTime":"0","summary":"Poster presentation on Monday, June 2, 2025 from 1:30 – 4:30 PM CDT at the ASCO Annual Meeting. MIAMI, April 24, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven indications, today announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the American Society for Clinical Oncology  taking place May 30 – June 3, 2025, in Chicago, Illinois.The Company will present updated interim clinical data from its onging Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid tumors.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-present-updated-data-110200343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B66KJ199.SGD","BK4157","AEIS","KTTA","PK","BK4139","LU1169590202.USD","KTTAW","BK4218","BK4135","IE0031619046.USD","IE00B7SZL793.SGD","LU1169589451.USD","BK4023","BK4181","IE00B19Z4B17.USD","CNS","PD","LENZ","BK4007"],"gpt_icon":0},{"id":"2526659586","title":"Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2526659586","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526659586?lang=en_us&edition=fundamental","pubTime":"2025-04-10 22:13","pubTimestamp":1744294382,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  said Thursday that the external Safety Review Committee recommended that the company's phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor, in advanced cancer should proceed to cohort 6, 30mg capsules, without any modification.The recommendation was based on the review of the safety data from three patients from cohort 5 and the absence of any dose limiting toxicities, or DLT, the biotechnology company said.During the DLT period, no rash was observed to date in any of the first 19 patients in either capsule or tablet formulation of PAS-004. Rash is a common adverse event that is observed at low doses with competitor MEK inhibitors, Pasithea said.Shares were up 50% in early Thursday trading.Price: 1.62, Change: +0.54, Percent Change: +50.00","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IE00B66KJ199.SGD","AEIS","BK6522","KTTA","LENZ","BK4157","BK6088","IE00B7SZL793.SGD","IE0031619046.USD","IE00B19Z4B17.USD","BLZ.SI","BK4139"],"gpt_icon":0},{"id":"2526554735","title":"BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526554735","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526554735?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:12","pubTimestamp":1744283522,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced CancerApril 10 (Reuters) - Pasithea Therapeut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN25E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2526846554","title":"Pasithea Therapeutics Corp - No Dose-Limiting Toxicities (Dlt's) or Rash Observed to Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846554?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:02","pubTimestamp":1744282923,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN25E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2526548425","title":"Pasithea Therapeutics Corp - Src Recommended That Trial Escalate to Next Dose Level of 30Mg Capsule","url":"https://stock-news.laohu8.com/highlight/detail?id=2526548425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526548425?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:02","pubTimestamp":1744282923,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN25E:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2526333554","title":"Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526333554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526333554?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:02","pubTimestamp":1744282923,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN25E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2526255278","title":"Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526255278","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526255278?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:02","pubTimestamp":1744282920,"startTime":"0","endTime":"0","summary":"–SRC recommended that the trial escalate to the next dose level of 30mg capsule –。“We are seeing substantial enrollment demand and have already identified Cohort 6 patients. In addition, we continue to observe substantial exposure levels of PAS-004, and remain excited about the possibility of delivering relevant pERK inhibition below the no observed adverse effect levels  as we modeled and observed during our previously conducted nine-month chronic toxicity studies. The on label rash rate for both approved MEKi for NF1 exceeds 80% which leads to patients discontinuing who otherwise should remain on treatment for longer periods of time”, stated Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “We will provide additional safety, pharmacokinetic  and pharmacodynamic  data over the next several weeks.”This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Ac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-positive-safety-110200309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","BK4218","LU1169589451.USD","BK4023","IE00B19Z4B17.USD","SRC","BK4157","BK4139","LU1169590202.USD","AEIS","IE00B66KJ199.SGD","IE00B7SZL793.SGD","KTTAW","BK4181","LENZ","BK4231","BK4135","BK4007","CNS","PD","PK","IE0031619046.USD","KTTA"],"gpt_icon":0},{"id":"2521746203","title":"Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746203","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746203?lang=en_us&edition=fundamental","pubTime":"2025-03-24 18:59","pubTimestamp":1742813940,"startTime":"0","endTime":"0","summary":"-- Conference taking place on March 27-29, 2025 in New Orleans -- -- CAGLA NeauxCancer Conference is a leading global forum in oncology -- MIAMI, March  24, 2025  (GLOBE NEWSWIRE) -- Pasithea Therapeu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047687/0/en/Pasithea-Therapeutics-to-Present-at-the-2025-CAGLA-NeauxCancer-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4181","KTTA","BK4218","PK","LENZ","CNS","BK4135"],"gpt_icon":0},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=fundamental","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHRRF","OPTHF","KTTA","QNTM","RLMD","MYCOF","PSYGF","NRXP","BK4168","BK4139","BETRF","SNPX","CYBN","BK4547","ENTBF","GHRS","ALID","SEEL","SILO","IXHL","SPRC","RVVTF","AGNPF","MIRA","MDXXF","DRUG","BK4202","NUMIF","CMPS","BK4539","BK4007","CMND","MNMD","PBM","ATAI","FLHLF"],"gpt_icon":0},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=fundamental","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IXHL","MYCOF","CMPS","BK4168","BK4139","NRXP","ENTBF","QNTM","FLHLF","OPTHF","PHRRF","PBM","CYBN","PSYGF","RVVTF","BK4547","KTTA","AGNPF","BK4202","BETRF","RLMD","SILO","CMND","NUMIF","MNMD","GHRS","BK4007","DRUG","MDXXF","SNPX","SPRC","ENVB","ATAI","BK4539","ALID","MIRA","SEEL"],"gpt_icon":0},{"id":"2509231345","title":"Crude Oil Down 2%; ISM Services PMI Falls In January","url":"https://stock-news.laohu8.com/highlight/detail?id=2509231345","media":"Benzinga","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509231345?lang=en_us&edition=fundamental","pubTime":"2025-02-06 01:17","pubTimestamp":1738775843,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/43502454/crude-oil-down-2-ism-services-pmi-falls-in-january","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACB","BK4093","BK4557","SQQQ","BK4232","FMC","NQmain","BK4139","LU0471298777.SGD","KTTA","USAW.SI","QLD","QID","USJW.SI","MNQmain","BK4007","BK4545","TQQQ","BK4091","BK4588","IE00BFMHRM44.USD","BK4585","PSQ","TSYW.SI","BK4009","LU0385154629.USD","BK4022",".IXIC","VLCN","NVIW.SI","CRTO","RXO"],"gpt_icon":1},{"id":"2509687282","title":"US Stocks Mixed; Walt Disney Posts Upbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2509687282","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509687282?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:44","pubTimestamp":1738766687,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/43496322/us-stocks-mixed-walt-disney-posts-upbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VLCN","DIS","KTTA","OGEN","ACB","FMC","LTRY"],"gpt_icon":1},{"id":"2509128186","title":"Pasithea Therapeutics Shares Rise After Positive Safety Review for Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2509128186","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509128186?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:04","pubTimestamp":1738764240,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  shares were up 67% to $3.46 in premarket trading after the company said that an external safety review committee recommended that its Phase 1 clinical trial of PAS-004 in advanced cancer should proceed to cohort 5, 22mg capsule, without modification.The biotechnology company said that this recommendation was based on the review of the safety data from three patients in cohort 4A, 15mg capsule, and the absence of any dose limiting toxicities.The Miami company also said that no rash had been observed to date in any of the first 14 patients who have been dosed with PAS-004 in either capsule or tablet formulation. Rash is a common adverse event that is observed at low doses with competitor inhibitors and may lead to the high discontinuation rate in real world practice.The continuing Phase 1 clinical trial is a multicenter, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, and preliminary efficacy of P","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","KTTA","BK4139"],"gpt_icon":1},{"id":"2509283487","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2509283487","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509283487?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:46","pubTimestamp":1738759584,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  shares soared 52% pre-bell Wednesday after the company said it received a positive recommendation from a safety review committee for its ongoing phase 1 trial of PAS-004 in advanced cancer to advance to the next dose cohort.Alliance Entertainment Holding  shares surged 20% following a muted session.1895 Bancorp of Wisconsin  shares were up 4.3%, adding to Tuesday's 2% gain.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4159","AENT","BK4139","KTTA","BK4195","BK4211","BCOW"],"gpt_icon":0},{"id":"2509040282","title":"Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2509040282","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509040282?lang=en_us&edition=fundamental","pubTime":"2025-02-05 19:59","pubTimestamp":1738756740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nTUA2DNQKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTAW","KTTA","BK4139"],"gpt_icon":0},{"id":"2509402104","title":"Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2509402104","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509402104?lang=en_us&edition=fundamental","pubTime":"2025-02-05 19:59","pubTimestamp":1738756740,"startTime":"0","endTime":"0","summary":"SRC recommended that the trial escalate to the next dose level of 22mg capsule. “As we are observing substantial exposure levels of PAS-004, we remain encouraged by the safety profile PAS-004 continues to exhibit,” stated Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “With the differentiated profile of PAS-004, we believe it is possible that this highly specific macrocyclic MEK inhibitor with a half life of greater than 60 hours may change the treatment paradigm for patients with NF1 and inoperable plexiform neurofibromas. We are looking forward to presenting updated pharmakokinetic  and pharmacodynamic  data during Q1 2025.”This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial and the saf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-positive-safety-115900013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SRC","AE","KTTA","BK4139","BK4218","BK4135","LU1169589451.USD","BK4157","BK4231","BK4138","IE0031619046.USD","CNS","BK4080","IE00B66KJ199.SGD","BK4023","PK","BK4181","LENZ","IE00B19Z4B17.USD","KTTAW","PD","IE00B7SZL793.SGD","LU1169590202.USD","AEIS"],"gpt_icon":1},{"id":"2503578092","title":"Pasithea Therapeutics opens three clinical trial sites in Eastern Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2503578092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503578092?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:31","pubTimestamp":1736861469,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) announced it has opened three clinical trial sites in Eastern Europe. These sites in Romania and Bulgaria are actively...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-opens-three-clinical-trial-sites-in-eastern-europe?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-opens-three-clinical-trial-sites-in-eastern-europe?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EML","LENZ","BK4139","KTTA","BK4161"],"gpt_icon":0},{"id":"2503527289","title":"Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4","url":"https://stock-news.laohu8.com/highlight/detail?id=2503527289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503527289?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:02","pubTimestamp":1736859720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUABLGWDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTAW","BK4139","KTTA"],"gpt_icon":0},{"id":"2503152037","title":"Pasithea Therapeutics Corp - to Present Interim Safety and Pk Data in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503152037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503152037?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:02","pubTimestamp":1736859720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUABLGWDM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTAW","BK4139","KTTA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KTTA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-24","symbol":"KTTA","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-2.41},{"market":"US","date":"2024-08-13","symbol":"KTTA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-3.71},{"market":"US","date":"2024-05-14","symbol":"KTTA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-3.7},{"market":"US","date":"2024-03-28","symbol":"KTTA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711598400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-01-02","symbol":"KTTA","defaultRemindTime":1704205800000,"type":"split","dateTimestamp":1704171600000,"forFactor":20,"toFactor":1,"ratio":20}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KTTA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KTTA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KTTA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KTTA","date":"2025-04-25","current":-0.334642,"percent":0.790194,"low":-1093.683193,"twenty":-8.982065,"median":-0.805313,"eighty":-0.326015,"high":-0.082689,"avg":-40.425536,"sd":151.589773,"marketCap":4653052},"quantilePoints":[{"date":"2021-08-13","current":-1093.683193,"twenty":-1093.683193,"median":-1093.683193,"eighty":-1093.683193,"marketCap":67235268},{"date":"2021-09-17","current":-669.104496,"twenty":-1093.683193,"median":-756.194287,"eighty":-671.674393,"marketCap":41133868},{"date":"2021-09-24","current":-626.621673,"twenty":-1093.683193,"median":-671.674393,"eighty":-632.994101,"marketCap":38522194},{"date":"2021-10-01","current":-609.628538,"twenty":-891.189849,"median":-656.359653,"eighty":-608.804372,"marketCap":37477524},{"date":"2021-10-08","current":-556.525018,"twenty":-729.430106,"median":-641.490663,"eighty":-578.616078,"marketCap":34212932},{"date":"2021-10-15","current":-632.994095,"twenty":-687.639563,"median":-626.621673,"eighty":-571.393991,"marketCap":38913945},{"date":"2021-10-22","current":-571.393991,"twenty":-671.674393,"median":-609.628538,"eighty":-571.393991,"marketCap":35127017},{"date":"2021-10-29","current":-601.13197,"twenty":-670.132455,"median":-607.568124,"eighty":-571.393991,"marketCap":36955189},{"date":"2021-11-05","current":-537.407736,"twenty":-661.45759,"median":-596.894317,"eighty":-566.296057,"marketCap":33037678},{"date":"2021-11-12","current":-548.02845,"twenty":-653.810678,"median":-586.262981,"eighty":-556.525018,"marketCap":33690597},{"date":"2021-11-19","current":-10.979296,"twenty":-648.287908,"median":-575.642283,"eighty":-545.904304,"marketCap":31303839},{"date":"2021-11-26","current":-18.576783,"twenty":-642.340318,"median":-572.456064,"eighty":-536.133248,"marketCap":52965567},{"date":"2021-12-03","current":-21.49554,"twenty":-635.54307,"median":-571.393991,"eighty":-511.493207,"marketCap":61287438},{"date":"2021-12-10","current":-17.503511,"twenty":-631.294785,"median":-567.145715,"eighty":-26.651141,"marketCap":49905485},{"date":"2021-12-17","current":-11.361928,"twenty":-627.896161,"median":-558.649148,"eighty":-21.219169,"marketCap":32394789},{"date":"2021-12-23","current":-15.430727,"twenty":-624.92236,"median":-556.525018,"eighty":-19.683773,"marketCap":43995625},{"date":"2021-12-31","current":-13.588252,"twenty":-616.425792,"median":-549.090515,"eighty":-17.135016,"marketCap":38742416},{"date":"2022-01-07","current":-11.438698,"twenty":-609.628538,"median":-545.904304,"eighty":-14.877985,"marketCap":32613672},{"date":"2022-01-14","current":-10.59423,"twenty":-609.216455,"median":-536.345663,"eighty":-14.064224,"marketCap":30205951},{"date":"2022-01-21","current":-9.596223,"twenty":-607.568124,"median":-527.849104,"eighty":-13.434712,"marketCap":27360463},{"date":"2022-01-28","current":-8.598216,"twenty":-601.13197,"median":-505.545611,"eighty":-11.515468,"marketCap":24514975},{"date":"2022-02-04","current":-9.135604,"twenty":-599.00784,"median":-30.170526,"eighty":-11.361928,"marketCap":26047161},{"date":"2022-02-11","current":-9.442684,"twenty":-594.780793,"median":-25.717878,"eighty":-10.979296,"marketCap":26922696},{"date":"2022-02-18","current":-8.367907,"twenty":-594.759548,"median":-21.265231,"eighty":-10.238077,"marketCap":23858324},{"date":"2022-02-25","current":-7.830518,"twenty":-587.962294,"median":-19.883375,"eighty":-9.964718,"marketCap":22326138},{"date":"2022-03-04","current":-8.674986,"twenty":-582.86436,"median":-18.576783,"eighty":-9.442684,"marketCap":24733859},{"date":"2022-03-11","current":-9.212374,"twenty":-576.916767,"median":-17.273201,"eighty":-9.35056,"marketCap":26266045},{"date":"2022-03-18","current":-10.210381,"twenty":-575.642283,"median":-15.430727,"eighty":-9.35056,"marketCap":29111533},{"date":"2022-03-25","current":-10.287151,"twenty":-573.942966,"median":-14.739799,"eighty":-9.365914,"marketCap":29330417},{"date":"2022-04-01","current":-13.65563,"twenty":-571.81882,"median":-14.35595,"eighty":-9.42733,"marketCap":29680798},{"date":"2022-04-08","current":-13.126342,"twenty":-571.393991,"median":-13.905179,"eighty":-9.442684,"marketCap":28530380},{"date":"2022-04-14","current":-14.290775,"twenty":-571.393991,"median":-13.751639,"eighty":-9.488745,"marketCap":31061300},{"date":"2022-04-22","current":-12.279481,"twenty":-570.119513,"median":-13.588252,"eighty":-9.565515,"marketCap":26689710},{"date":"2022-04-29","current":-12.702912,"twenty":-567.995373,"median":-13.285128,"eighty":-9.596223,"marketCap":27610045},{"date":"2022-05-06","current":-10.967906,"twenty":-567.145715,"median":-13.126342,"eighty":-9.596223,"marketCap":23838973},{"date":"2022-05-13","current":-9.630924,"twenty":-565.871227,"median":-13.073413,"eighty":-9.617044,"marketCap":20933015},{"date":"2022-05-20","current":-6.517075,"twenty":-561.198116,"median":-13.020484,"eighty":-9.488745,"marketCap":20842597},{"date":"2022-05-27","current":-6.082361,"twenty":-557.37467,"median":-12.649983,"eighty":-9.335206,"marketCap":19452314},{"date":"2022-06-03","current":-7.244512,"twenty":-556.525018,"median":-12.385339,"eighty":-9.289144,"marketCap":23169050},{"date":"2022-06-10","current":-7.427281,"twenty":-556.525018,"median":-12.385339,"eighty":-9.135604,"marketCap":23753574},{"date":"2022-06-17","current":-7.427281,"twenty":-553.976043,"median":-12.279481,"eighty":-8.936003,"marketCap":23753574},{"date":"2022-06-24","current":-7.093053,"twenty":-549.727754,"median":-12.279481,"eighty":-8.69034,"marketCap":22684663},{"date":"2022-07-01","current":-7.281648,"twenty":-547.603621,"median":-11.976086,"eighty":-8.306491,"marketCap":23287818},{"date":"2022-07-08","current":-7.791364,"twenty":-545.904304,"median":-11.515468,"eighty":-8.191854,"marketCap":24917965},{"date":"2022-07-15","current":-9.147016,"twenty":-545.904304,"median":-11.435659,"eighty":-8.082629,"marketCap":29253549},{"date":"2022-07-22","current":-9.432861,"twenty":-543.780158,"median":-11.361928,"eighty":-8.166979,"marketCap":30167723},{"date":"2022-07-29","current":-9.473696,"twenty":-537.407736,"median":-11.086562,"eighty":-8.191854,"marketCap":30298319},{"date":"2022-08-05","current":-10.127054,"twenty":-535.28359,"median":-10.967906,"eighty":-8.214367,"marketCap":32387858},{"date":"2022-08-12","current":-10.780413,"twenty":-533.159461,"median":-10.725706,"eighty":-8.291137,"marketCap":34477398},{"date":"2022-08-19","current":-6.949802,"twenty":-522.538747,"median":-10.59423,"eighty":-8.082629,"marketCap":35642748},{"date":"2022-08-26","current":-6.194955,"twenty":-520.414601,"median":-10.479076,"eighty":-7.830518,"marketCap":31771438},{"date":"2022-09-02","current":-5.986721,"twenty":-505.545611,"median":-10.363921,"eighty":-7.791364,"marketCap":30703491},{"date":"2022-09-09","current":-6.455247,"twenty":-497.049053,"median":-10.238077,"eighty":-7.500098,"marketCap":33106373},{"date":"2022-09-16","current":-6.559364,"twenty":-125.08671,"median":-10.210381,"eighty":-7.427135,"marketCap":33640346},{"date":"2022-09-23","current":-6.194955,"twenty":-28.696546,"median":-10.208724,"eighty":-7.354465,"marketCap":31771438},{"date":"2022-09-30","current":-6.559364,"twenty":-26.296891,"median":-10.091948,"eighty":-7.310774,"marketCap":33640346},{"date":"2022-10-07","current":-6.403188,"twenty":-25.76283,"median":-9.980072,"eighty":-7.237376,"marketCap":32839386},{"date":"2022-10-14","current":-6.507305,"twenty":-25.410799,"median":-9.903302,"eighty":-7.06116,"marketCap":33373360},{"date":"2022-10-21","current":-5.518195,"twenty":-22.263238,"median":-9.630924,"eighty":-6.814917,"marketCap":28300609},{"date":"2022-10-28","current":-5.622312,"twenty":-21.127045,"median":-9.596223,"eighty":-6.757186,"marketCap":28834583},{"date":"2022-11-04","current":-6.159301,"twenty":-20.175099,"median":-9.555365,"eighty":-6.611422,"marketCap":31588583},{"date":"2022-11-11","current":-5.988209,"twenty":-19.837313,"median":-9.494114,"eighty":-6.559364,"marketCap":30711122},{"date":"2022-11-18","current":-3.744034,"twenty":-19.683773,"median":-9.442684,"eighty":-6.515619,"marketCap":30658474},{"date":"2022-11-25","current":-3.607588,"twenty":-19.007296,"median":-9.432861,"eighty":-6.507305,"marketCap":29541174},{"date":"2022-12-02","current":-3.679026,"twenty":-18.521192,"median":-9.392026,"eighty":-6.455247,"marketCap":30126148},{"date":"2022-12-09","current":-3.500432,"twenty":-17.895759,"median":-9.365914,"eighty":-6.382365,"marketCap":28663714},{"date":"2022-12-16","current":-2.714621,"twenty":-17.22714,"median":-9.310356,"eighty":-6.278248,"marketCap":22229002},{"date":"2022-12-23","current":-2.062755,"twenty":-16.305902,"median":-9.289144,"eighty":-6.245813,"marketCap":16891117},{"date":"2022-12-30","current":-2.292069,"twenty":-15.661036,"median":-9.289144,"eighty":-6.194955,"marketCap":18768883},{"date":"2023-01-06","current":-2.309214,"twenty":-15.369311,"median":-9.229503,"eighty":-6.161226,"marketCap":18909276},{"date":"2023-01-13","current":-2.488168,"twenty":-15.06293,"median":-9.179695,"eighty":-6.142896,"marketCap":20374665},{"date":"2023-01-20","current":-2.447802,"twenty":-14.820063,"median":-9.135604,"eighty":-6.090838,"marketCap":20044125},{"date":"2023-01-27","current":-2.489236,"twenty":-14.816569,"median":-8.982065,"eighty":-6.045239,"marketCap":20383410},{"date":"2023-02-03","current":-2.421728,"twenty":-14.663029,"median":-8.86691,"eighty":-5.986721,"marketCap":19830610},{"date":"2023-02-10","current":-2.088826,"twenty":-14.35595,"median":-8.697833,"eighty":-5.934662,"marketCap":17104603},{"date":"2023-02-17","current":-2.096687,"twenty":-14.290775,"median":-8.636601,"eighty":-5.726429,"marketCap":17168979},{"date":"2023-02-24","current":-1.752716,"twenty":-14.158667,"median":-8.534493,"eighty":-5.622312,"marketCap":14352331},{"date":"2023-03-03","current":-1.780577,"twenty":-14.064224,"median":-8.291137,"eighty":-5.171792,"marketCap":14580470},{"date":"2023-03-10","current":-1.729249,"twenty":-13.818964,"median":-8.20311,"eighty":-3.679026,"marketCap":14160167},{"date":"2023-03-17","current":-1.535904,"twenty":-13.745731,"median":-8.082629,"eighty":-3.607588,"marketCap":12576935},{"date":"2023-03-24","current":-1.428748,"twenty":-13.672862,"median":-7.885734,"eighty":-3.570084,"marketCap":11699475},{"date":"2023-03-31","current":-1.339451,"twenty":-13.601728,"median":-7.830518,"eighty":-3.500432,"marketCap":10968258},{"date":"2023-04-05","current":-1.428391,"twenty":-13.526836,"median":-7.810941,"eighty":-3.465357,"marketCap":11696550},{"date":"2023-04-14","current":-0.749882,"twenty":-13.39605,"median":-7.718547,"eighty":-2.874212,"marketCap":10450696},{"date":"2023-04-21","current":-0.836681,"twenty":-13.316885,"median":-7.500098,"eighty":-2.62461,"marketCap":11660364},{"date":"2023-04-28","current":-0.656147,"twenty":-13.211028,"median":-7.436975,"eighty":-2.543242,"marketCap":9144359},{"date":"2023-05-05","current":-0.581159,"twenty":-13.126342,"median":-7.426917,"eighty":-2.49638,"marketCap":8099289},{"date":"2023-05-12","current":-0.674894,"twenty":-13.126342,"median":-7.354465,"eighty":-2.482807,"marketCap":9405626},{"date":"2023-05-18","current":-0.558853,"twenty":-13.126342,"median":-7.354465,"eighty":-2.427442,"marketCap":8885704},{"date":"2023-05-26","current":-0.600098,"twenty":-13.126342,"median":-7.33626,"eighty":-2.358077,"marketCap":9541485},{"date":"2023-06-02","current":-0.575285,"twenty":-13.062827,"median":-7.281648,"eighty":-2.303499,"marketCap":9146971},{"date":"2023-06-09","current":-0.79531,"twenty":-13.020484,"median":-7.244512,"eighty":-2.280424,"marketCap":12645342},{"date":"2023-06-16","current":-0.761131,"twenty":-13.020484,"median":-7.134559,"eighty":-2.147122,"marketCap":12101905},{"date":"2023-06-23","current":-0.709863,"twenty":-12.978141,"median":-7.063199,"eighty":-2.090973,"marketCap":11286751},{"date":"2023-06-30","current":-0.788737,"twenty":-12.808769,"median":-6.990382,"eighty":-2.071684,"marketCap":12540835},{"date":"2023-07-07","current":-0.838033,"twenty":-12.724083,"median":-6.819656,"eighty":-2.046396,"marketCap":13324637},{"date":"2023-07-14","current":-0.755052,"twenty":-12.639397,"median":-6.767598,"eighty":-1.946312,"marketCap":12005237},{"date":"2023-07-21","current":-0.974419,"twenty":-12.512368,"median":-6.767598,"eighty":-1.782717,"marketCap":15493156},{"date":"2023-07-28","current":-0.971133,"twenty":-12.385339,"median":-6.650466,"eighty":-1.757289,"marketCap":15440903},{"date":"2023-08-04","current":-0.973269,"twenty":-12.385339,"median":-6.611422,"eighty":-1.737636,"marketCap":15474868},{"date":"2023-08-11","current":-1.029301,"twenty":-12.385339,"median":-6.559364,"eighty":-1.647346,"marketCap":16365772},{"date":"2023-08-18","current":-0.922144,"twenty":-12.385339,"median":-6.559364,"eighty":-1.54019,"marketCap":15680815},{"date":"2023-08-25","current":-0.936135,"twenty":-12.342996,"median":-6.513434,"eighty":-1.443036,"marketCap":15918720},{"date":"2023-09-01","current":-0.930908,"twenty":-12.279481,"median":-6.507305,"eighty":-1.400387,"marketCap":15829832},{"date":"2023-09-07","current":-0.9532,"twenty":-12.279481,"median":-6.507305,"eighty":-1.339451,"marketCap":16208912},{"date":"2023-09-15","current":-0.799458,"twenty":-12.279481,"median":-6.507305,"eighty":-1.028381,"marketCap":13594571},{"date":"2023-09-22","current":-0.544841,"twenty":-12.279481,"median":-6.455247,"eighty":-0.986118,"marketCap":9264880},{"date":"2023-09-29","current":-0.551575,"twenty":-12.189568,"median":-6.403188,"eighty":-0.977377,"marketCap":9379390},{"date":"2023-10-06","current":-0.518763,"twenty":-12.037502,"median":-6.320693,"eighty":-0.970344,"marketCap":8821415},{"date":"2023-10-13","current":-0.530699,"twenty":-11.976086,"median":-6.247013,"eighty":-0.956072,"marketCap":9024389},{"date":"2023-10-20","current":-0.575911,"twenty":-11.699715,"median":-6.247013,"eighty":-0.93715,"marketCap":9793212},{"date":"2023-10-23","current":-0.575911,"twenty":-11.607592,"median":-6.247013,"eighty":-0.935766,"marketCap":9793212},{"date":"2023-11-03","current":-0.39211,"twenty":-11.454052,"median":-6.205643,"eighty":-0.929985,"marketCap":6667719},{"date":"2023-11-10","current":-0.459259,"twenty":-11.438698,"median":-6.194955,"eighty":-0.92073,"marketCap":7809566},{"date":"2023-11-17","current":-0.390317,"twenty":-11.433836,"median":-6.159301,"eighty":-0.839196,"marketCap":6257237},{"date":"2023-11-24","current":-0.402144,"twenty":-11.390205,"median":-6.151098,"eighty":-0.827299,"marketCap":6446851},{"date":"2023-12-01","current":-0.42372,"twenty":-11.361928,"median":-6.10227,"eighty":-0.805526,"marketCap":6792739},{"date":"2023-12-08","current":-0.428009,"twenty":-11.315866,"median":-6.090838,"eighty":-0.797799,"marketCap":6861499},{"date":"2023-12-15","current":-0.482209,"twenty":-11.185028,"median":-6.067797,"eighty":-0.787784,"marketCap":7730387},{"date":"2023-12-22","current":-0.37173,"twenty":-11.080219,"median":-6.002517,"eighty":-0.7805,"marketCap":5959274},{"date":"2023-12-29","current":-0.506905,"twenty":-11.039738,"median":-5.988209,"eighty":-0.774737,"marketCap":8126282},{"date":"2024-01-05","current":-0.490144,"twenty":-10.994407,"median":-5.986721,"eighty":-0.773619,"marketCap":7857593},{"date":"2024-01-12","current":-0.487408,"twenty":-10.970184,"median":-5.986721,"eighty":-0.764089,"marketCap":7813732},{"date":"2024-01-19","current":-0.454914,"twenty":-10.929162,"median":-5.874148,"eighty":-0.758896,"marketCap":7292817},{"date":"2024-01-26","current":-0.452965,"twenty":-10.829581,"median":-5.726429,"eighty":-0.751007,"marketCap":7261562},{"date":"2024-02-02","current":-0.428919,"twenty":-10.714765,"median":-5.67437,"eighty":-0.72911,"marketCap":6876084},{"date":"2024-02-09","current":-0.378229,"twenty":-10.624938,"median":-5.600708,"eighty":-0.690979,"marketCap":6063456},{"date":"2024-02-16","current":-0.470303,"twenty":-10.59423,"median":-5.518195,"eighty":-0.661662,"marketCap":7539522},{"date":"2024-02-23","current":-0.467912,"twenty":-10.588724,"median":-3.750463,"eighty":-0.651122,"marketCap":7501183},{"date":"2024-03-01","current":-0.519902,"twenty":-10.555264,"median":-3.679026,"eighty":-0.62303,"marketCap":8334648},{"date":"2024-03-08","current":-0.467918,"twenty":-10.486753,"median":-3.607588,"eighty":-0.60253,"marketCap":7501287},{"date":"2024-03-15","current":-0.467912,"twenty":-10.440691,"median":-3.607588,"eighty":-0.583874,"marketCap":7501183},{"date":"2024-03-22","current":-0.466066,"twenty":-10.409983,"median":-3.57187,"eighty":-0.577049,"marketCap":7471595},{"date":"2024-03-28","current":-0.464662,"twenty":-10.348567,"median":-3.536865,"eighty":-0.575543,"marketCap":7449091},{"date":"2024-04-05","current":-0.57144,"twenty":-10.277336,"median":-3.500432,"eighty":-0.575034,"marketCap":9121131},{"date":"2024-04-12","current":-0.499602,"twenty":-10.232538,"median":-3.465071,"eighty":-0.559641,"marketCap":7974474},{"date":"2024-04-19","current":-0.466948,"twenty":-10.210381,"median":-2.953758,"eighty":-0.555795,"marketCap":7453267},{"date":"2024-04-26","current":-0.472826,"twenty":-10.210381,"median":-2.714621,"eighty":-0.546188,"marketCap":7547084},{"date":"2024-05-03","current":-0.451927,"twenty":-10.210381,"median":-2.602107,"eighty":-0.539063,"marketCap":7213511},{"date":"2024-05-10","current":-0.501555,"twenty":-10.21005,"median":-2.572103,"eighty":-0.531663,"marketCap":8005642},{"date":"2024-05-17","current":-0.416074,"twenty":-10.193701,"median":-2.505399,"eighty":-0.520528,"marketCap":6775697},{"date":"2024-05-24","current":-0.419288,"twenty":-10.1323,"median":-2.491379,"eighty":-0.517907,"marketCap":6828026},{"date":"2024-05-31","current":-0.374766,"twenty":-10.127054,"median":-2.488168,"eighty":-0.505605,"marketCap":6103000},{"date":"2024-06-07","current":-0.36451,"twenty":-10.056842,"median":-2.456196,"eighty":-0.501555,"marketCap":5935976},{"date":"2024-06-14","current":-0.365112,"twenty":-10.047676,"median":-2.425835,"eighty":-0.493908,"marketCap":5945783},{"date":"2024-06-21","current":-0.314054,"twenty":-10.006197,"median":-2.408333,"eighty":-0.492726,"marketCap":5114314},{"date":"2024-06-28","current":-0.336969,"twenty":-9.980072,"median":-2.377973,"eighty":-0.490144,"marketCap":5487484},{"date":"2024-07-05","current":-0.331844,"twenty":-9.956506,"median":-2.333681,"eighty":-0.487408,"marketCap":5404024},{"date":"2024-07-12","current":-0.336329,"twenty":-9.912764,"median":-2.294926,"eighty":-0.482209,"marketCap":5477052},{"date":"2024-07-15","current":-0.358751,"twenty":-9.903302,"median":-2.293497,"eighty":-0.482209,"marketCap":5842188},{"date":"2024-08-02","current":-0.320954,"twenty":-9.903302,"median":-2.292069,"eighty":-0.481169,"marketCap":5226672},{"date":"2024-08-09","current":-0.310704,"twenty":-9.891593,"median":-2.279389,"eighty":-0.474405,"marketCap":5059752},{"date":"2024-08-16","current":-0.292199,"twenty":-9.80199,"median":-2.153123,"eighty":-0.473282,"marketCap":4788508},{"date":"2024-08-23","current":-0.299561,"twenty":-9.623984,"median":-2.117225,"eighty":-0.472794,"marketCap":4909164},{"date":"2024-08-30","current":-0.300103,"twenty":-9.596223,"median":-2.088826,"eighty":-0.470393,"marketCap":4918039},{"date":"2024-09-06","current":-0.272682,"twenty":-9.596223,"median":-2.071684,"eighty":-0.467918,"marketCap":4468666},{"date":"2024-09-13","current":-0.251339,"twenty":-9.596223,"median":-2.055611,"eighty":-0.466948,"marketCap":4118899},{"date":"2024-09-20","current":-0.305811,"twenty":-9.556182,"median":-2.005265,"eighty":-0.464662,"marketCap":5011588},{"date":"2024-09-27","current":-0.372708,"twenty":-9.555365,"median":-1.857015,"eighty":-0.464013,"marketCap":6107873},{"date":"2024-10-04","current":-0.333462,"twenty":-9.519453,"median":-1.780577,"eighty":-0.462388,"marketCap":5464719},{"date":"2024-10-11","current":-0.307723,"twenty":-9.514531,"median":-1.762986,"eighty":-0.459259,"marketCap":5042911},{"date":"2024-10-18","current":-0.254206,"twenty":-9.473696,"median":-1.752716,"eighty":-0.454914,"marketCap":4165883},{"date":"2024-10-25","current":-0.257597,"twenty":-9.473696,"median":-1.739733,"eighty":-0.453887,"marketCap":4221452},{"date":"2024-10-31","current":-0.251858,"twenty":-9.448886,"median":-1.696995,"eighty":-0.452009,"marketCap":4127410},{"date":"2024-11-08","current":-0.232092,"twenty":-9.442684,"median":-1.64306,"eighty":-0.451927,"marketCap":3803486},{"date":"2024-11-15","current":-0.264925,"twenty":-9.434826,"median":-1.559122,"eighty":-0.448416,"marketCap":4179209},{"date":"2024-11-22","current":-0.255291,"twenty":-9.400193,"median":-1.53519,"eighty":-0.441407,"marketCap":4027237},{"date":"2024-11-29","current":-0.248066,"twenty":-9.392026,"median":-1.464467,"eighty":-0.436176,"marketCap":3913259},{"date":"2024-12-06","current":-0.22639,"twenty":-9.392026,"median":-1.42857,"eighty":-0.428919,"marketCap":3571324},{"date":"2024-12-13","current":-0.214348,"twenty":-9.376359,"median":-1.339451,"eighty":-0.427079,"marketCap":3381360},{"date":"2024-12-20","current":-0.214348,"twenty":-9.365914,"median":-1.339272,"eighty":-0.42489,"marketCap":3381360},{"date":"2024-12-27","current":-0.223982,"twenty":-9.343691,"median":-1.028151,"eighty":-0.42257,"marketCap":3533331},{"date":"2025-01-03","current":-0.235221,"twenty":-9.310356,"median":-1.010569,"eighty":-0.421624,"marketCap":3710631},{"date":"2025-01-10","current":-0.224785,"twenty":-9.310356,"median":-0.986085,"eighty":-0.419171,"marketCap":3545995},{"date":"2025-01-17","current":-0.196687,"twenty":-9.310356,"median":-0.982799,"eighty":-0.415922,"marketCap":3102746},{"date":"2025-01-24","current":-0.199898,"twenty":-9.293386,"median":-0.974419,"eighty":-0.403234,"marketCap":3153403},{"date":"2025-01-31","current":-0.18063,"twenty":-9.289144,"median":-0.972201,"eighty":-0.402144,"marketCap":2849460},{"date":"2025-02-07","current":-0.1718,"twenty":-9.289144,"median":-0.961273,"eighty":-0.392063,"marketCap":2710153},{"date":"2025-02-14","current":-0.117209,"twenty":-9.289144,"median":-0.955593,"eighty":-0.387742,"marketCap":1848983},{"date":"2025-02-21","current":-0.108378,"twenty":-9.27737,"median":-0.940824,"eighty":-0.3827,"marketCap":1709676},{"date":"2025-02-28","current":-0.097942,"twenty":-9.24551,"median":-0.936135,"eighty":-0.373943,"marketCap":1545040},{"date":"2025-03-07","current":-0.097139,"twenty":-9.219226,"median":-0.930908,"eighty":-0.369851,"marketCap":1532376},{"date":"2025-03-14","current":-0.083491,"twenty":-9.212374,"median":-0.928755,"eighty":-0.36451,"marketCap":1317084},{"date":"2025-03-21","current":-0.094731,"twenty":-9.173159,"median":-0.922298,"eighty":-0.358765,"marketCap":1494383},{"date":"2025-03-28","current":-0.256818,"twenty":-9.140169,"median":-0.914919,"eighty":-0.347994,"marketCap":3570947},{"date":"2025-04-04","current":-0.24709,"twenty":-9.135604,"median":-0.83876,"eighty":-0.336713,"marketCap":3435684},{"date":"2025-04-11","current":-0.311294,"twenty":-9.135604,"median":-0.828668,"eighty":-0.333105,"marketCap":4328420},{"date":"2025-04-17","current":-0.266546,"twenty":-9.074188,"median":-0.824365,"eighty":-0.330695,"marketCap":3706210},{"date":"2025-04-25","current":-0.334642,"twenty":-8.982065,"median":-0.805313,"eighty":-0.326015,"marketCap":4653052}],"updateTime":1745775761698}}}